Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : University of Washington
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
April 07, 2022
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : University of Washington
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : John Yu
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
February 08, 2021
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : John Yu
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tozuleristide
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access for BLZ-100 (Tozuleristide)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
April 13, 2020
Lead Product(s) : Tozuleristide
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Pacific Pediatric Neuro-Oncology Consortium
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
July 06, 2018
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Pacific Pediatric Neuro-Oncology Consortium
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
July 14, 2015
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
June 08, 2015
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of BLZ-100 in Pediatric Subjects With CNS Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
June 04, 2015
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
September 09, 2014
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety Study of a Fluorescent Marker to Visualize Cancer Cells
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
March 27, 2014
Lead Product(s) : Tozuleristide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable